receptor targets raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
=== Electrodiagnostic testing === Electromyography (EMG) and nerve conduction studies help distinguish myopathic from neurogenic causes of weakness and may show characteristic myopathic motor unit potentials or myotonic discharges. A myopathic EMG combined with proximal weakness and hyperCKemia substantially increases the likelihood of a positive muscle biopsy, although a normal EMG does not exclude myopathy.
Aden soon became an important transit port and coaling station for trade between British India and the Far East, and Europe. The commercial and strategic importance of Aden increased considerably when the Suez Canal opened in 1869. From then and until the 1960s, the Port of Aden was to be one of the busiest ship-bunkering, duty-free shopping, and trading ports in the world. In 1937, Aden was separated from British India to become a Crown colony, a status that it retained until 1963. It consisted of the port city of Aden and its immediate surroundings (an area of 192 km2 [74 sq mi]). The Aden Settlement, and later Aden Colony, also included the outlying islands of Kamaran (de facto), Perim and Kuria Muria (see map). Prior to 1937, Aden had been governed as part of British India (originally as the Aden Settlement under the Bombay Presidency, and then as a Chief Commissioner's province). Under the Government of India Act 1935 the territory was detached from British India, and was re-organised as a separate Crown colony of the United Kingdom; this separation took effect on 1 April 1937. Through the latter years of its existence, Aden Colony was plagued by civil unrest.
=== Selenophosphate synthetase === The production of selenoprotein cannot occur without selenophosphate, which is produced by selenophosphate synthetase. Vertebrates including humans carry two versions of this enzyme, with one (SEPHS2) being a selenoprotein and the other (SEPHS1) replacing it with a threonine, though still with a vestigial SECIS element. Analysis of animal versions of this enzyme show that the original animal version is a selenoprotein, with SEPHS1 arising later through gene duplication. Among prokaryotes, most bacteria have a version with cystine instad of selenocystine, suggesting that this may be the ancestral state (which would avoid the chicken-and-egg problem). Some have two versions, one with Sec and the other with Cys. Archaea mostly have the Sec version.
For instance, in Mexico in 2009, "personal use" quantities were established for a number of drugs – cannabis (5 g), cocaine (0.5 g), heroin (50 mg), methamphetamine (40 mg), LSD (0.015 mg) – possession of which would result in a referral for treatment. A 2023 briefing to the European Parliament noted: "The UN bodies monitoring compliance with the conventions seem to have come to accept these policy choices" of tolerance or administrative rather than criminal penalties.
Sources: en.wikipedia.org
It is unclear that cyproheptadine achieves adequate serotonin 5-HT2A receptor occupancy at the assessed doses. Further complicating the picture, high doses of cyproheptadine have been reported to produce partial LSD-like discriminative stimulus effects in animals.
== Trade names == Several companies have attempted to trademark particular strains, and as a marketing technique, have invented scientific-sounding names for the strains. Danone (Dannon in the United States) markets the subspecies strain DN 173 010 as Bifidus Digestivum (UK), Bifidus Regularis (US and Mexico), Bifidobacterium Lactis or B.L. Regularis (Canada), DanRegularis (Brazil), Bifidus Actiregularis (Argentina, Austria, Belgium, Bulgaria, Chile, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Kazakhstan, Netherlands, Portugal, Romania, Russia, South Africa, Spain and the UK), and Bifidus Essensis in the Middle East (and formerly in Hungary, Bulgaria, Romania and The Netherlands) through Activia from Safi Danone KSA. One notable example involved Danone’s attempt to enforce a trademark on an invented probiotic strain name. Danone held a trademark for “Bifidus Essensis”, which it used in marketing its Activia products, and sued Glanbia after the launch of Yoplait “Essence” products in the Irish market, claiming trademark infringement. In 2007, the Irish Commercial Court ruled against Danone, finding that the “Essensis” trademark had not been genuinely used as a product brand in the relevant market and ordering its revocation in that context. Chr. Hansen A/S from Denmark has a similar claim on a strain of Bifidobacterium animalis subsp. lactis, marketed under the trademark BB-12. Lidl lists "Bifidobacterium BB-12" in its "Proviact" yogurt. Bifidobacterium lactis Bl-04 and Bi-07 are strains from DuPont's Danisco FloraFIT range.
The objective of an atomic bomb is to produce a device, according to Serber, "...in which energy is released by a fast neutron chain reaction in one or more of the materials known to show nuclear fission." According to Rhodes, "Untamped, a bomb core even as large as twice the critical mass would completely fission less than 1 percent of its nuclear material before it expanded enough to stop the chain reaction from proceeding. Tamper always increased efficiency: it reflected neutrons back into the core and its inertia...slowed the core's expansion and helped keep the core surface from blowing away." Rearrangement of the core material's subcritical components would need to proceed as fast as possible to ensure effective detonation. Additionally, a third basic component was necessary, "...an initiator—a Ra + Be source or, better, a Po + Be source, with the radium or polonium attached perhaps to one piece of the core and the beryllium to the other, to smash together and spray neutrons when the parts mated to start the chain reaction." However, any bomb would "necessitate locating, mining and processing hundreds of tons of uranium ore...", while U-235 separation or the production of Pu-239 would require additional industrial capacity.
=== Academia === Prior to his postdoctoral fellowship, Kopeček served as the research scientific officer for the Institute of Macromolecular Chemistry at the Czechoslovak Academy of Sciences from 1965 to 1967. He then served in the same capacity after his postdoctoral fellowship at the National Research Council of Canada until 1972, when he became the head of the Laboratory of Medical Polymers at the Institute of Macromolecular Chemistry from 1972 to 1980. Kopeček then became head of the Laboratory of Biodegradable Polymers until 1988. In 1986, Kopeček became co-director for the Center of Controlled Chemical Delivery of Utah and was a visiting professor. From 1989, he was professor of bioengineering and professor of pharmaceutics and pharmaceutical chemistry. As of 2002, Kopeček has been a distinguished professor in both pharmaceutical chemistry and biomedical engineering. In 2017, he became the director for the Center of Controlled Chemical Delivery at the University of Utah.
For each diprotic acid titration curve, from left to right, there are two midpoints, two equivalence points, and two buffer regions. Due to the successive dissociation processes, there are two equivalence points in the titration curve of a diprotic acid. The first equivalence point occurs when all first protons from the first ionization are titrated. In other words, the amount of OH− added equals the original amount of H2A at the first equivalence point. The second equivalence point occurs when all protons are titrated. Therefore, the amount of OH− added equals twice the amount of H2A at this time. For a weak diprotic acid titrated by a strong base, the second equivalence point must occur at pH above 7 due to the hydrolysis of the resulted salts in the solution. At either equivalence point, adding a drop of base will cause the steepest rise of the pH value in the system.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.